Clinical trials
Phase 2 Study clinical trials
Below are recruiting phase 2 study clinical trials, each written for real people, not researchers. We’re tracking 1,327 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07118527RecruitingPhase 3
New drug combo for untreated advanced stomach cancer
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
Shenyang, LiaoningAges 18–75 - NCT07123454RecruitingPhase 1/Phase 2
Study of AZD4512 for relapsed or refractory B-cell lymphoma
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
Irvine, CaliforniaAges 18 years+ - NCT04254419RecruitingPhase 1
Natural killer cell injections in the brain tumor area
This early-phase trial tests injections of lab-grown immune cells directly into (or near) a brain tumor. It aims to see if the treatment is safe and can help control recurrent, progressive, or resistant CNS tumors.
Columbus, OhioAges 1–39 - NCT07115446RecruitingPhase 1
Study of HS-20093 and HRS-5041 for advanced prostate cancer
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
ShanghaiAges 18 years+ - NCT07110038RecruitingPhase 2
Study of Enfortumab Vedotin Plus Avelumab for Advanced Penile Cancer
This trial tests a combination of two drugs (enfortumab vedotin and avelumab) as a first treatment for men with advanced or metastatic penile cancer that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors and improve outcomes.
DresdenAges 18 years+ - NCT07106671RecruitingPhase 2
Siltuximab for side effects after CAR-T in multiple myeloma
This trial tests if the drug Siltuximab can help control side effects (CRS and ICANS) that sometimes happen after CAR-T treatment for multiple myeloma. It may help patients who develop these symptoms.
TianjinAges 18 years+ - NCT06307925RecruitingPhase 1
HC010 for advanced solid tumors: a safety and early efficacy study
This trial is testing a new drug (HC010) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe, how it works in the body, and whether it can shrink tumors.
Guangzhou, GuangdongAges 18–75 - NCT06968572RecruitingPhase 1
New drug for MTAP-deleted solid tumors
This trial tests a new experimental drug (HSK41959) for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and effective for tumors that no longer respond to standard treatments.
Guiyang, GuizhouAges 18 years+ - NCT07101432RecruitingPhase 1
Radiation plus engineered NK cells for advanced head and neck cancer
This early-phase trial tests a new type of immune cell therapy combined with radiation for advanced head and neck cancer. The cells are engineered to target the TROP2 marker on cancer cells and are given after a short course of radiation to help them work better.
Houston, TexasAges 18 years+ - NCT07100873RecruitingPhase 1
Testing a new drug for rheumatoid arthritis
This trial tests a new medication called ADI-001 to see if it can help people with rheumatoid arthritis. It is for adults who meet the standard criteria for RA and are in generally good health otherwise.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07105215RecruitingPhase 1/Phase 2
Testing RC278 for Solid Tumors
This study tests a new drug called RC278 for people with solid tumors that have not spread to the brain. It aims to see if the drug is safe and effective, and may be an option for those who are otherwise fairly healthy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06459687RecruitingPhase 3
Socazolimab for first-line treatment of advanced cervical cancer
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
Hefei, AnhuiAges 18–75 - NCT07089199RecruitingPhase 2
Treatment before surgery for stage 2–3 lung cancer
This study tests whether giving a combination of three medicines before surgery can help shrink tumors in people with stage 2 or 3 non-small cell lung cancer, potentially making surgery and recovery more effective. The medicines include an immunotherapy drug (tislelizumab), a targeted therapy (anlotinib), and a chemotherapy drug (nab-paclitaxel).
Jinan, ShandongAges 18–75 - NCT07093866RecruitingPhase 2
Targeted drug combo for advanced prostate cancer
This trial tests a combination of two drugs—disitamab vedotin (a targeted antibody-drug that attacks HER2-positive cancer cells) and abiraterone (a hormone therapy)—to see if they can slow or shrink prostate cancer that has spread and become resistant to standard treatments.
Nanjing, JiangsuAges 18–75 - NCT07087223RecruitingPhase 1/Phase 2
Study of vebreltinib plus furmonertinib for NSCLC with c-Met amplification
This trial tests a combination of two targeted therapies (vebreltinib and furmonertinib) for people with a specific type of advanced non-small cell lung cancer (NSCLC) that has a change called c-Met amplification and has stopped responding to earlier EGFR-targeted treatment. It aims to see if adding vebreltinib can help control the cancer.
Neimeng, NeimengAges 18 years+ - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT06853444RecruitingPhase 1/Phase 2
ESG206 for adults with hard-to-treat ITP
This trial tests a new drug called ESG206 for adults with immune thrombocytopenia (ITP) whose platelet counts remain very low despite previous treatments like steroids or IVIG. The goal is to see if ESG206 can safely help raise platelet levels and reduce bleeding risk.
Jinan, ShandongAges 18 years+ - NCT07081646RecruitingPhase 1/Phase 2
CAR T cell therapy for AL amyloidosis
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
Phoenix, ArizonaAges 18 years+ - NCT07083323RecruitingPhase 1/Phase 2
Study of HY05350 for mesothelin-positive advanced solid tumors
This clinical trial tests an experimental drug called HY05350 for people with advanced solid tumors that have a specific protein (mesothelin). It aims to see if the drug is safe and effective for cancers that have not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT07085338RecruitingPhase 2
N-803 with chemoimmunotherapy for relapsed neuroblastoma
This trial tests adding a new drug called N-803 to a standard chemo-immunotherapy combination for children and young adults with high-risk neuroblastoma that has come back or not responded to previous treatments. The goal is to see if this combination works better at fighting the cancer.
San Francisco, CaliforniaAges Up to 30 years - NCT07085182RecruitingPhase 2
Tislelizumab plus radiation for advanced lung cancer
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
Zibo, ShandongAges 18–75 - NCT06474442RecruitingPhase 2
BD111 gene therapy for herpes simplex virus eye infection
This trial tests a new gene therapy called BD111 for people with a herpes simplex virus infection in the cornea (the clear front part of the eye). It aims to see if the treatment is safe and can help clear the virus, possibly improving vision.
Wenzhou, ZhejiangAges 18–70 - NCT06977893RecruitingPhase 3
Chemo and immunotherapy for HR+ breast cancer before surgery
This trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery helps women with a certain type of breast cancer (HR+, HER2-). It aims to see if this combination works better than chemotherapy alone.
HangzhouAges 18–75
Hear when a new Phase 2 Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2 study?
- Yes. Clin2 currently lists 1,327 recruiting phase 2 study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.